NCT04033159 - Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions

Centronuclear Myopathy

Interventions

DRUG

DYN101

DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA

Trial Locations (8)

Antwerp University Hospital (UZA), Edegem

Rigshospitalet, Copenhagen Neuromuscular Center, Neurocentret, Copenhagen

Institut de Myologie, Paris

universitätsklinikum Essen, Kinderklinik I, Sozialpädiatrisches Zentrum, Essen

Friedrich Baur Institut - Neurologische Klinik LMV, Klinikum Innenstadt, München

Radboud University Medical Centre, Nijmegen

MRC centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery, London

Royal Victoria Infirmary, Newcastle upon Tyne